Heart Outcomes Prevention Evaluation: SOLARIS Study of Lipid Modification and Blood Pressure Reduction in People at Average Risk - HOPE-3

The HOPE-3 trial will evaluate the benefits of combined cholesterol and blood pressure lowering therapies in reducing cardiovascular risk in a wide group of people without vascular disease.

Aims

HOPE-3 is expected to identify safe and effective cardiovascular prevention strategies which could substantially reduce the risk of cardiovascular disease (CVD) in a large proportion of middle aged people who are at average risk for vascular events.

Methods

HOPE-3 is a large, simple, multicentre, randomised, placebo-controlled trial evaluating the effects of lipid modification and blood pressure lowering with rosuvastatin and a combination of candesartan/hydrochlorothiazide and their combination.

A total of 10,000 participants will be recruited in approximately 10 countries and followed for the occurrence of major vascular events over an average of 5 years.

Simple eligibility criteria will be used based on the absence of pre-existent atherothrombotic vascular disease and age, as the major determinant of risk, in addition to one additional CV risk factor and a clinician’s assessment as to whether an individual does or does not have a clear indication or a contraindication for the therapies being evaluated.

Institute Investigators

Collaboration